Techinvention Lifecare engaged by Botswana Vaccine Institute for new state-of-the-art veterinary vaccine facility

2 July 2024

Techinvention Lifecare Private Limited has been appointed as a consultant by Botswana Vaccine Institute (BVI) to monitor setting up of the new state-of-the-art and cGMP compliant, vaccine manufacturing unit in its existing facility at Gaborone, Botswana.

The scope encompasses comprehensive project management role for the state-owned Botswana Vaccine Institute (BVI), that has been manufacturing and supplying critical veterinary vaccines since the 1970s, in the region and beyond.

The project involves setting up a new blending and filling block for veterinary vaccines, which would be compliant with cGMP requirements alongside other stringent global standards and guidelines.

The initiative aims to enhance the capacity, number of products, quality, efficacy, and safety of the products while ensuring that all regulatory approvals are secured, thus enabling BVI to offer more products that are required in the region and explore new markets.

The project commenced in 2022 and is expected to be completed and operational by 2026.

Techinvention CEO Syed Ahmed has expressed complete support to BVI for getting the proposed facility operational in the stipulated timeframe. He has emphasised the strategic significance and the pressing need of the region for such a facility.

for his part, BVI CEO Andrew Madeswi reiterated the commitment of strengthening the capability to manufacture a range of vaccines in the proposed state-of-the-art facility with cGMP compliance to ensure access to affordable, high quality products for the country, region and beyond.

Source: https://www.biospectrumindia.com/news/16/24848/techinvention-lifecare-engaged-by-botswana-vaccine-institute-for-new-state-of-the-art-veterinary-vaccine-facility.html

3 weeks ago

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.